Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807859 · ClinicalTrials.gov registry record · Phase 1
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00807859: Completed Phase 1 study, sponsored by Amgen.
NCT00807859 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 65 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00807859, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if AMG 386 in combination with either paclitaxel and trastuzumab or capecitabine and lapatinib is safe and well tolerated in subjects with HER2-positive locally recurrent or metastatic breast cancer. This is an open-label phase 1b trial and has 2 study parts. Study part 1 is a dose escalation study to determine a tolerable dose of AMG 386 in combination with paclitaxel and trastuzumab (cohort A) or with capecitabine and lapatinib (cohort B). Study part 2 is cohort expansion of the tolerable doses determined in part 1.
Interventions
- DRUG AMG 386 30 mg/kg, Paclitaxel and Trastuzumab
- DRUG AMG 386 30 mg/kg, Capecitabine and Lapatinib
- DRUG AMG 386 10 mgkg, Paclitaxel and Trastuzumab
- DRUG AMG 386 10 mg/kg, Capecitabine and Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2009-03-09 |
| Est. Completion | 2015-10-19 |
| Phase | Phase 1 |
What the finished NCT00807859 record still lists
NCT00807859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which AMG 386 30 mg/kg, Paclitaxel and Trastuzumab is the first listed.
NCT00807859 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00807859 about?
NCT00807859 is a clinical study titled "Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer". The purpose of this study is to determine if AMG 386 in combination with either paclitaxel and trastuzumab or capecitabine and lapatinib is safe and well tolerated in subjects with HER2-positive locally recurrent or metastatic breast cancer. This is an open-label phase 1b trial and has 2 study part...
What is the current status of trial NCT00807859?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2009-03-09. Estimated completion is 2015-10-19.
What interventions are being tested in trial NCT00807859?
The interventions under investigation include: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab (DRUG), AMG 386 30 mg/kg, Capecitabine and Lapatinib (DRUG), AMG 386 10 mgkg, Paclitaxel and Trastuzumab (DRUG), AMG 386 10 mg/kg, Capecitabine and Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00807859?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00807859's enrollment target sits among peer trials
65 798th of 2000 higher than 1,193 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI